natgillin/translations-raw huggingface dataset:
In patients treated with dabrafenib in combination with trametinib with suspected ILD or pneumonitis, including patients presenting with new or progressive pulmonary symptoms and findings including cough, dyspnoea, hypoxia, pleural effusion, or infiltrates, pending clinical investigations, please refer to the trametinib SmPC (see section 4.2) for dose modification instructions for trametinib.
U bolesnika liječenih dabrafenibom u kombinaciji s trametinibom u kojih se sumnja na IBP ili pneumonitis, uključujući bolesnike u kojih se pojave novi ili progrediraju postojeći plućni simptomi i nalazi uključujući kašalj, dispneju, hipoksiju, pleuralni izljev ili infiltrate, sve dok se ne provedu kliničke pretrage, pogledajte Sažetak opisa svojstava lijeka za trametinib (dio 4.2) za uputu za prilagodbe doze trametiniba.
In patients treated with docetaxel at 100 mg/m2 as single agent who have serum transaminase levels (ALT and/or AST) greater than 1.5 times the ULN concurrent with serum alkaline phosphatase levels greater than 2.5 times the ULN, there is a higher risk of developing severe adverse reactions such as toxic deaths including sepsis and gastrointestinal haemorrhage which can be fatal, febrile neutropenia, infections, thrombocytopenia, stomatitis and asthenia.
U bolesnika koji su primali docetaksel u dozi od 100 mg/m2 kao jedinu terapiju te imali vrijednosti transaminaza (ALT i/ili AST) u serumu više od 1,5 puta veće od GGN, te serumsku alkalnu fosfatazu više od 2,5 puta veću od GGN, postoji viši rizik od razvoja teških nuspojava poput toksične smrti uključujući sepsu i gastrointestinalno krvarenje koje može biti fatalno, febrilne neutropenije, infekcije, trombocitopenije, stomatitisa i astenije.
In patients treated with docetaxel at 100 mg/m2 as single agent who have serum transaminase levels (ALT and/or AST) greater than 1.5 times the ULN concurrent with serum alkaline phosphatase levels greater than 2.5 times the ULN, there is a higher risk of developing severe adverse reactions such as toxic deaths including sepsis and gastrointestinal haemorrhage which can be fatal, febrile neutropenia, infections, thrombocytopenia, stomatitis and asthenia.
U bolesnika koji su primali docetaksel u dozi od 100 mg/m2 kao jedinu terapiju te imali vrijednosti transaminaza (ALT i/ili AST) u serumu više od 1,5 puta veće od GGN, te serumsku alkalnu fosfatazu više od 2,5 puta veću od GGN, postoji viši rizik od razvoja teških nuspojava poput toksične smrti uključujući sepsu i gastrointestinalno krvarenje koji mogu biti fatalni, febrilne neutropenije, infekcije, trombocitopenije, stomatitisa i astenije.
In patients treated with docetaxel at 100 mg/m² as single agent who have serum transaminase levels (ALT and/or AST) greater than 1.5 times the ULN concurrent with serum alkaline phosphatase levels greater than 2.5 times the ULN, there is a higher risk of developing severe adverse reactions such as toxic deaths including sepsis and gastrointestinal haemorrhage which can be fatal, febrile neutropenia, infections, thrombocytopenia, stomatitis and asthenia.
U bolesnika koji su primali docetaksel u dozi od 100 mg/m2 kao jedinu terapiju te imali vrijednosti transaminaza (ALT i/ili AST) u serumu više od 1,5 puta veće od GGN, te serumsku alkalnu fosfatazu više od 2,5 puta veću od GGN, postoji viši rizik od razvoja teških nuspojava poput toksične smrti uključujući sepsu i gastrointestinalno krvarenje koje može biti fatalno, febrilne neutropenije, infekcije, trombocitopenije, stomatitisa i astenije.
In patients treated with docetaxel every three weeks, the incidence of related nail changes occurred at a rate ≥ 10 % higher in patients who were 65 years of age or greater compared to younger patients.
U bolesnika koji su docetaksel primali svaka tri tjedna, incidencija promjena na noktima povezanih s uzimanjem lijeka bila je ≥10% viša u bolesnika u dobi od 65 godina ili starijih u usporedbi s mlađim bolesnicima.
In patients treated with docetaxel in combination with doxorubicin and cyclophosphamide (TAC), febrile neutropena and/or neutropenic infection occurred at lower rates when patients received primary G-CSF prophylaxis.
U bolesnika liječenih docetakselom u kombinaciji s doksorubicinom i ciklofosfamidom (TAC), febrilna neutropenija i/ili neutropenijska infekcija rijeđe su zabilježene ako su bolesnici dobivali primarnu G-CSF profilaksu.
In patients treated with doses
U bolesnika liječenih dozama
In patients treated with either 15 mg twice daily Xarelto followed by 20 mg once daily for treatment of DVT or PE, or with 20 mg once daily for prevention of recurrent DVT and PE, bleeding events occurred in approximately 27.8 % of patients and anaemia occurred in approximately 2.2 % of patients.
U bolesnika koji su dobivali Xarelto 15 mg dvaput na dan, a zatim 20 mg jedanput na dan za liječenje DVT-a ili plućne embolije, ili 20 mg jedanput na dan za prevenciju ponavljajućeg DVT-a i plućne embolije krvarenje se dogodilo u oko 27,8% bolesnika, a anemija u oko 2,2% bolesnika.
In patients treated with either 15 mg twice daily Xarelto followed by 20 mg once daily for treatment of DVT or PE, or with 20 mg once daily for prevention of recurrent DVT and PE, bleeding events occurred in approximately 27.8 % of patients and anaemia occurred in approximately 2.2 % of patients.
U bolesnika koji su dobivali Xarelto 15 mg dvaput na dan, a zatim 20 mg jedanput na dan za liječenje DVT-a ili plućne embolije, ili 20 mg jedanput na dan za prevenciju ponavljajućeg DVT-a i plućne embolije, krvarenje se dogodilo u oko 27,8% bolesnika, a anemija u oko 2,2% bolesnika.
In patients treated with either 15 mg twice daily Xarelto followed by 20 mg once daily for treatment of DVT or PE, or with 20 mg once daily for prevention of recurrent DVT and PE, bleeding events occurred in approximately 27.8% of patients and anaemia occurred in approximately 2.2% of patients.
U bolesnika koji su dobivali Xarelto 15 mg dvaput na dan, a zatim 20 mg jedanput na dan za liječenje DVT-a ili plućne embolije, ili 20 mg jedanput na dan za prevenciju ponavljajućeg DVT-a i plućne embolije krvarenje se dogodilo u oko 27,8% bolesnika, a anemija u oko 2,2% bolesnika.
In patients treated with G+ B, 79.4% received all six treatment cycles compared to 66.7% of patients in the B arm.
Svih šest ciklusa liječenja primilo je 79,4% bolesnika liječenih kombinacijom G+B, u usporedbi sa 66,7% bolesnika u skupini koja je primala samo B.
In patients treated with myeloablative therapy followed by bone marrow transplantation
Kod bolesnika liječenih mijeloablativnom terapijom nakon presađivanja koštane srži
In patients treated with nivolumab in combination with ipilimumab, the incidence of diarrhoea or colitis was 45.5% (204/448).
U bolesnika liječenih nivolumabom u kombinaciji s ipilimumabom, incidencija proljeva ili kolitisa iznosila je 45,5% (204/448).
In patients treated with nivolumab in combination with ipilimumab, the incidence of hypersensitivity/infusion reactions was 3.8% (17/448); all were Grade 1 or 2 in severity.
U bolesnika liječenih nivolumabom u kombinaciji s ipilimumabom, incidencija reakcija preosjetljivosti/reakcija na infuziju iznosila je 3,8% (17/448); svi su slučajevi bili 1. ili 2. stupnja težine.
In patients treated with nivolumab in combination with ipilimumab, the incidence of liver function test abnormalities was 27.9% (125/448).
U bolesnika liječenih nivolumabom u kombinaciji s ipilimumabom, incidencija odstupanja u nalazima testova jetrene funkcije iznosila je 27,9% (125/448).
In patients treated with nivolumab in combination with ipilimumab, the incidence of nephritis and renal dysfunction was 4.2% (19/448).
U bolesnika liječenih nivolumabom u kombinaciji s ipilimumabom, incidencija nefritisa i bubrežne disfunkcije iznosila je 4,2% (19/448).
In patients treated with nivolumab in combination with ipilimumab, the incidence of pneumonitis including interstitial lung disease, was 7.4% (33/448).
U bolesnika liječenih nivolumabom u kombinaciji s ipilimumabom, incidencija pneumonitisa, uključujući intersticijsku bolest pluća, iznosila je 7,4% (33/448).
In patients treated with nivolumab in combination with ipilimumab, the incidence of rash was 63.4% (284/448).
U bolesnika liječenih nivolumabom u kombinaciji s ipilimumabom, incidencija osipa iznosila je 63,4% (284/448).
In patients treated with nivolumab in combination with ipilimumab, the incidence of thyroid disorders was 23.7% (106/448).
U bolesnika liječenih nivolumabom u kombinaciji s ipilimumabom, incidencija poremećaja štitnjače iznosila je 23,7% (106/448).
In patients treated with nivolumab in combination with ipilimumab, the proportion of patients who experienced a worsening from baseline to a Grade 3 or 4 laboratory abnormality was as follows: 2.8% for anaemia (all Grade 3), 1.2% for thrombocytopaenia, 0.5% for leucopoenia, 6.4% for lymphopaenia, 0.7% for neutropaenia, 4.1% for increased alkaline phosphatase, 11.9% for increased AST, 14.6% for increased ALT, 0.9% for increased total bilirubin, 2.4% for increased creatinine, 8.5% for increased amylase, 18.2% for increased lipase, 1.3% for hypocalcaemia, 0.3% each for hypercalcaemia, hyperkalemia, hypermagnesaemia, and hypernatraemia, 4.5% for hypokalaemia, and 9.2% for hyponatraemia.
U bolesnika liječenih nivolumabom u kombinaciji s ipilimumabom, udio bolesnika kod kojih je došlo do pogoršanja početnih laboratorijskih vrijednosti do 3. ili 4. stupnja bio je sljedeći: 2,8% za anemiju (svi slučajevi bili su 3. stupnja), 1,2% za trombocitopeniju, 0,5% za leukopeniju, 6,4% za limfopeniju, 0,7% za neutropeniju, 4,1% za povišene razine alkalne fosfataze, 11,9% za povišene razine AST-a, 14,6% za povišene razine ALT-a, 0,9% za povišene razine ukupnog bilirubina, 2,4% za povišene razine kreatinina, 8,5% za povišene razine amilaze, 18,2% za povišene razine lipaze, 1,3% za hipokalcijemiju, 0,3% za hiperkalcijemiju, hiperkalijemiju, hipermagnezijemiju i hipernatrijemiju, 4,5% za hipokalijemiju i 9,2% za hiponatrijemiju.
In patients treated with nivolumab monotherapy, the incidence of diarrhoea or colitis was 13.6% (235/1728).
U bolesnika liječenih monoterapijom nivolumabom, incidencija proljeva ili kolitisa iznosila je 13,6% (235/1728).
In patients treated with nivolumab monotherapy, the incidence of hypersensitivity/infusion reactions was 4.1% (71/1728), including 3 Grade 3 and 2 Grade 4 cases.
U bolesnika liječenih monoterapijom nivolumabom, incidencija reakcija preosjetljivosti/reakcija na infuziju iznosila je 4,1% (71/1728), uključujući 3 slučaja 3. stupnja i 2 slučaja 4. stupnja.
In patients treated with nivolumab monotherapy, the incidence of liver function test abnormalities was 7.0% (121/1728).
U bolesnika liječenih monoterapijom nivolumabom, incidencija odstupanja u nalazima testova jetrene funkcije iznosila je 7,0% (121/1728).
In patients treated with nivolumab monotherapy, the incidence of nephritis or renal dysfunction was 3.2% (55/1728).
U bolesnika liječenih monoterapijom nivolumabom, incidencija nefritisa ili bubrežne disfunkcije iznosila je 3,2% (55/1728).
In patients treated with nivolumab monotherapy, the incidence of pneumonitis, including interstitial lung disease, was 3.2% (56/1728).
U bolesnika liječenih monoterapijom nivolumabom, incidencija pneumonitisa, uključujući intersticijsku bolest pluća, iznosila je 3,2% (56/1728).
In patients treated with nivolumab monotherapy, the incidence of rash was 28.0% (484/1728).
U bolesnika liječenih monoterapijom nivolumabom, incidencija osipa iznosila je 28,0% (484/1728).
In patients treated with nivolumab monotherapy, the incidence of thyroid disorders, including hypothyroidism or hyperthyroidism, was 8.6% (149/1728).
U bolesnika liječenih monoterapijom nivolumabom, incidencija poremećaja štitnjače, uključujući hipotireozu ili hipertireozu, iznosila je 8,6% (149/1728).
In patients treated with other medicinal products associated with liver toxicity, monitoring of liver enzymes is also recommended.
Nadzor jetrenih enzima preporučuje se i u pacijenata koji primaju druge lijekove uz koje je vezana toksičnost za jetru.
In patients treated with Pom + LD-Dex, no peripheral neuropathy reactions were reported to have been serious in clinical trials and peripheral neuropathy led to dose discontinuation in 0.3% of patients (see section 4.4).
U bolesnika liječenih s Pom + LD-Dex, periferna neuropatija nije bila zabilježena kao ozbiljna u kliničkim ispitivanjima, a periferna neuropatija je dovela do prekida terapije u 0,3% bolesnika (vidjeti dio 4.4).
In patients treated with prolonged-release exenatide, generally 20 % reported at least one episode of nausea compared to 34 % of immediate-release exenatide patients.
Općenito je barem jednu epizodu mučnine prijavilo 20% bolesnika liječenih eksenatidom s produljenim oslobađanjem u usporedbi s 34% bolesnika koji su primali eksenatid s trenutnim oslobađanjem.
In patients treated with TAGRISSO 80 mg once daily, dose reductions due to ADRs occurred in 2.2% of the patients.
U bolesnika liječenih lijekom TAGRISSO u dozi od 80 mg jedanput dnevno, do smanjenja doze zbog nuspojava došlo je u 2,2% bolesnika.
In patients treated with teriparatide, lumbar spine, total hip and femoral neck BMD increased between 18 and 24 months by an additional 1.7 %, 0.9 %, and 0.4 %, respectively.
U bolesnika liječenih teriparatidom se između 18. i 24. mjeseca liječenja BMD lumbalnog dijela kralježnice povećao za 1,7%, BMD cijelog kuka za 0,9%, a BMD vrata bedrene kosti za 0,4%.
In patients treated with zoledronic acid, no osteomalacia, marrow fibrosis or woven bone formation was detected.
U bolesnica liječenih zoledronatnom kiselinom nisu otkriveni osteomalacija, fibroza srži niti stvaranje ne- lamelarne kosti.
In patients treated with Zontivity the concomitant use of heparin (including LMWH) might be associated with an increased risk of bleeding and caution is advised. (See section 4.4.)
U bolesnika liječenih lijekom Zontivity istodobna primjena heparina (uključujući heparin male molekulske mase) može biti povezana s povećanim rizikom od krvarenja te se savjetuje oprez (vidjeti dio 4.4).
In patients undergoing a hip replacement, 1.4% of the patients who completed treatment with Eliquis (27 out of 1,949) had a clotting event or died from any cause, compared with 3.9% (74 out of 1,917) of the patients taking enoxaparin.
U bolesnika podvrgnutih kirurškoj zamjeni kuka, 1,4% bolesnika koji su primili terapiju lijekom Eliquis (27 od 1.949) stvorio se ugrušak ili su umrli od bilo kojeg uzroka, u usporedbi s 3,9% (74 od 1.917) bolesnika koji su uzimali enoksaparin.
In patients undergoing a knee replacement, the corresponding numbers were 15% (147 out of 976) for Eliquis compared with 24% (243 out of 997) for enoxaparin.
U bolesnika koji su podvrgnuti kirurškom zahvatu zamjene koljena, odgovarajuće brojke iznose 15% (147 od 976) za Eliquis u usporedbi s 24% (243 od 997) za enoksaparin.
In patients undergoing a stem cell or bone marrow transplant, Graft versus host disease (GvHD) may occur- this is a reaction of the donor cells against the patient receiving the transplant; signs and symptoms include rash on the palms of your hands and soles of your feet and ulcer and sores in your mouth, gut, liver, skin, or your eyes, lungs, vagina and joints.
U bolesnika kojima će se presaditi matične stanice ili koštana srž može se razviti bolest presatka protiv primatelja (GvHD) – to je reakcija stanica darivatelja protiv bolesnika koji prima presadak; znakovi i simptomi uključuju osip na dlanovima i tabanima te čireve i ranice u ustima, crijevima, jetri, koži ili očima, plućima, rodnici i zgobovima.
In patients undergoing a stem cell or bone marrow transplant, Graft versus host disease (GvHD) may occur- this is a reaction of the donor cells against the patient receiving the transplant; signs and symptoms include rash on the palms of your hands or soles of your feet and ulcer and sores in your mouth, gut, liver, skin, or your eyes, lungs, vagina and joints.
Kod bolesnika koji se podvrgavaju transplantaciji matičnih stanica ili koštane srži, može se javiti bolest presatka protiv primatelja (GvHD) – to je reakcija stanica davatelja protiv bolesnika koji prima transplantat; znakovi i simptomi uključuju osip na dlanovima ili tabanima i ulceracije i rane u ustima, trbuhu, jetri,koži ili na očima, plućima, vagini i zglobovima.
In patients undergoing ART procedures the risk of multiple pregnancy is related mainly to the number of embryos replaced, their quality and the patient age.
Kod pacijentica u kojih se provode postupci MPO rizik od višeplodnih trudnoća povezan je uglavnom s brojem vraćenih embrija, njihovom kvalitetom i dobi pacijentice.
In patients undergoing ART procedures the risk of multiple pregnancy is related mainly to the number of embryos replaced, their quality and the patient age.
Rizik višeplodne trudnoće nakon metoda medicinski potpomognute oplodnje povezan je s brojem prenesenih embrija, njihovom kvalitetom i godinama pacijentice.
In patients undergoing CABG, the incidence of bleeding was not increased by eptifibatide compared to the patients treated with placebo.
U bolesnika podvrgnutih CABG-u, incidencija krvarenja nije bila povišena primjenom eptifibatida u usporedbi s ispitanicima na placebu.
In patients undergoing CABG, the incidence of bleeding was not increased by Integrilin compared to the patients treated with placebo.
U bolesnika podvrgnutih CABG-u, incidencija krvarenja nije bila povišena primjenom INTEGRILINa u usporedbi s ispitanicima na placebu.
In patients undergoing coronary catheterisation, pulsed-wave Doppler ultrasonography was used to measure the average peak velocity (APV) of CBF before and up to 30 minutes after administration of Rapiscan (400 micrograms, intravenously).
U bolesnika podvrgnutih kateterizaciji srca pomoću pulsne Doppler-ultrasonografije mjerena je prosječna vršna brzina (Average Peak Velocity - APV ) koronarnog protoka krvi (Coronary Blood Flow - CBF) prije primjene Rapiscana i do 30 minuta nakon njegove primjene (400 mikrograma, intravenski).
In patients undergoing general surgery, the initial dose should be given 2 hours pre-operatively.
U bolesnika koji će biti podvrgnuti kirurškom zahvatu iz područja opće kirurgije, početna doza mora se dati 2 sata prije operacije.
In patients undergoing heart surgery, an increase in pulmonary artery pressure due to pulmonary vaso- constriction is frequently seen.
U bolesnika koji su podvrgnuti operaciji srca zabilježeno je učestalo povećanje plućnog arterijskog tlaka zbog pulmonalne vazokonstrikcije.
In patients undergoing hip replacement surgery
U bolesnika podvrgnutih kirurškom zahvatu ugradnje endoproteze kuka
In patients undergoing knee replacement surgery
U bolesnika podvrgnutih kirurškom zahvatu ugradnje endoproteze koljena
In patients undergoing major orthopaedic surgery, epidural or spinal haematomas that may result in long-term or permanent paralysis cannot be excluded with the concurrent use of fondaparinux and spinal/epidural anaesthesia or spinal puncture.
Kod velikih ortopedskih kirurških zahvata, pri istodobnoj primjeni fondaparinuksa i spinalne/epiduralne anestezije ili spinalne punkcije ne može se isključiti mogućnost nastanka epiduralnih ili spinalnih hematoma koji mogu uzrokovati dugotrajnu ili trajnu paralizu bolesnika.
In patients undergoing myelosuppressive or myeloablative therapy followed by autologous PBPC transplantation
Bolesnici u tijeku mijelosupresivnog i mijeloablativnog liječenja nakon kojeg slijedi transplantacija autolognih stanica preteča periferne krvi
In patients undergoing PCI, standard procedural adjunctive therapy should be implemented (see section 5.1).
U bolesnika koji se podvrgavaju PCI, mora se provesti standardna proceduralna dodatna terapija (vidjeti dio 5.1).
In patients undergoing peritoneal dialysis additional monitoring of fat- soluble vitamins and folic acid is recommended, since vitamin A, D, E and K levels were not measured in a clinical study in these patients.
U bolesnika na peritonealnoj dijalizi preporučuje se dodatno praćenje razine vitamina topivih u mastima i folne kiseline, jer se u kliničkom ispitivanju u tih bolesnika nisu mjerile vrijednosti vitamina A, D, E i K.
In patients undergoing peritoneal dialysis additional monitoring of fat-soluble vitamins and folic acid is recommended, since vitamin A, D, E and K levels were not measured in a clinical study in these patients.
U bolesnika na peritonejskoj dijalizi preporučuje se dodatno praćenje razine vitamina topivih u mastima i folne kiseline, jer se u kliničkom ispitivanju u tih bolesnika nisu mjerile vrijednosti vitamina A, D, E i K.
In patients weighing 80 kg or more, 100 mg (the contents of 1 pre-filled pen) 4 weeks after your last treatment, then every 4 weeks thereafter.
U bolesnika tjelesne težine 80 kg ili veće primjenjuje se doza od 100 mg (sadržaj 1 napunjene brizgalice) 4 tjedna nakon posljednjeg liječenja, a zatim svaka 4 tjedna nakon toga.
In patients weighing 80 kg or more, 100 mg (the contents of 2 pre-filled syringes) 4 weeks after your last treatment, then every 4 weeks thereafter.
U bolesnika tjelesne težine 80 kg ili veće primjenjuje se doza od 100 mg (sadržaj 2 napunjene štrcaljke) 4 tjedna nakon posljednjeg liječenja, a zatim svaka 4 tjedna nakon toga.
In patients where the use of systemic fusidic acid is considered essential, statin treatment should be discontinued throughout the duration of fusidic acid treatment.
U bolesnika u kojih je primjena sistemske fusidatne kiseline smatra neophodnom, liječenje statinom mora se prekinuti za cijelo vrijeme liječenja fusidatnom kiselinom.
In patients who achieved CR or CRi, the median duration of remission was 10.4 months (95% CI = 7.2, 15.2) for the Vidaza subjects and 12.3 months (95% CI = 9.0, 17.0) for the CCR subjects.
U bolesnika koji su postigli potpunu remisiju ili potpunu remisjiju s nepotpunim oporavkom krvne slike, medijan trajanja remisije iznosio je 10,4 mjeseca (95 % CI = 7,2; 15,2) u ispitanika liječenih Vidazom i 12,3 mjeseca (95 % CI = 9,0; 17,0) u ispitanika liječenih
In patients who anticipate a frequent use of CIALIS (i.e., at least twice weekly) a once daily regimen with the lowest doses of CIALIS might be considered suitable, based on patient choice and the physician’s judgement.
U bolesnika koji očekuju učestalu primjenu lijeka CIALIS (tj. najmanje dvaput tjedno) možda će biti primjerena primjena najniže doze lijeka jedanput na dan, ovisno o želji bolesnika i prosudbi liječnika.
In patients who anticipate a frequent use of tadalafil (i.e., at least twice weekly) a once daily regimen with the lowest doses of tadalafil might be considered suitable, based on patient choice and the physician’s judgement.
U bolesnika koji očekuju učestalu primjenu tadalafila (tj. najmanje dvaput tjedno) možda će biti primjerena primjena najniže doze tadalafila jedanput na dan, ovisno o želji bolesnika i prosudbi liječnika.
in patients who are already taking a combination of linagliptin and metformin as separate tablets; in combination with a sulphonylurea or insulin (other types of diabetes medicines) in patients who are not satisfactorily controlled on this medicine and metformin.
u bolesnika koji već uzimaju kombinaciju linagliptina i metformina kao zasebne tablete; u kombinaciji sa sulfonilurejom ili inzulinom (drugim tipovima lijekova protiv dijabetesa) u bolesnika kod kojih nije postignuta zadovoljavajuća kontrola stanja ovim lijekom i metforminom.
in patients who are already taking a combination of sitagliptin and metformin as separate tablets; in combination with a sulphonylurea, a PPAR-gamma agonist such as a thiazolidinedione, or insulin (other types of diabetes medicine) in patients who are not satisfactorily controlled on this medicine and metformin.
u bolesnika koji već uzimaju kombinaciju sitagliptina i metformina kao zasebne tablete; u kombinaciji sa sulfonilurejom, agonistom PPAR-gama poput tiazolidinediona, ili inzulinom (drugim tipovima lijeka za dijabetes) u bolesnika čije se stanje ne može u zadovoljavajućoj mjeri kontrolirati ovim lijekom i metforminom.